drugset / Trial / NCT06205797
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
RandomizedParallel-groupDouble-blindTreatment
Summary
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Timeline
- Start
- 2024-06-20
- Primary completion
- 2024-11-30
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 4 iu | Intramuscular |
Indications
No indication recorded.